Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Ecnoglutide (XW003) is a long-acting, cAMP-signalling-biased GLP-1 analogue from Sciwind Biosciences. Derived from GLP-1(7-37) with an alanine-to-valine substitution at position 8, it activates the GLP-1 receptor selectively via the cAMP pathway over β-arrestin recruitment. Investigated for weight management and in type 2 diabetes.
Researched for
Weight management in overweight and obesityGlycaemic control in type 2 diabetes
Official status
US: Unapproved
No FDA approval. In the US ecnoglutide is an investigational agent available only within clinical research.
Ecnoglutide is a modified GLP-1(7-37) peptide with an alanine-to-valine substitution at position 8 and an 18-C fatty-acid conjugation at the lysine-30 side chain. It is a so-called biased agonist: at the GLP-1 receptor it preferentially induces cAMP formation while β-arrestin recruitment is reduced. In preclinical models this has been linked to lower receptor internalisation and desensitisation. GLP-1 receptor activation is mechanistically associated with enhanced glucose-dependent insulin secretion, delayed gastric emptying and satiety signalling. The fatty-acid conjugation enables weekly administration via albumin binding.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · single evidence tier
Human RCT
4
03
What the studies show
Human RCT
Mensch
Zhu D. et al. 2024
Statistically significant HbA1c reduction versus placebo in adults with type 2 diabetes over 20 weeks observed in a phase-2 trial
What does NOT follow: Phase-2 trial conducted in China with limited participant numbers and 20-week duration; generalisability to other populations and long-term safety are therefore not established.
Human RCT
Mensch
Wang Y. et al. 2025
Weight reduction versus placebo in adults with overweight or obesity without diabetes over 48 weeks documented in the phase-3 SLIMMER trial
What does NOT follow: Single trial in a predominantly Chinese population; head-to-head comparisons with other incretin therapies are largely absent. Describes a trial result, not a usage implication.
Human RCT
Mensch
Zhu D. et al. 2026
HbA1c control versus placebo as monotherapy in type 2 diabetes reported in the phase-3 EECOH-1 trial
What does NOT follow: Manufacturer-sponsored trial; the full safety and efficacy picture emerges only from the overall programme and independent replication.
Human RCT
Mensch
Zhu D. et al. 2024
Gastrointestinal events (diarrhoea, nausea, constipation) were the most frequent treatment-emergent adverse events in the phase-2 diabetes trial
What does NOT follow: Profile similar to other GLP-1 receptor agonists; frequencies come from a single trial and are not interpretable as individual risk.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 144 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
Administered as a once-weekly subcutaneous injection in the clinical trials.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
From a single phase-2 trial; often dose-dependent and transient. No statement about individual risk.
häufigste behandlungsbedingte Ereignisse in Phase 2
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Limited long-term and non-China data
The trials published to date were predominantly conducted in China and cover comparatively short periods. Long-term cardiovascular outcomes and data in other populations are not yet established.
11
Legal status by country
Country
Status
Note
Checked
United States
Unapproved
No FDA approval. In the US ecnoglutide is an investigational agent available only within clinical research.
2026-06-07
Germany
Unapproved
No EMA approval. Not authorised in Germany; investigational status, availability only via clinical trials.
2026-06-07
CN
Prescription
China's National Medical Products Administration (NMPA) has approved ecnoglutide injection in China — per the manufacturer for chronic weight management in adults with overweight/obesity (March 2026) and for type 2 diabetes. It is therefore available on prescription in China, while it remains investigational outside China.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
SampleAdults (18–75 y) with overweight/obesity without diabetes (China); SLIMMER trial.
EndpointPercentage weight change and proportion with ≥5% weight loss at 40 weeks.
MethodOnce-weekly subcutaneous dosing (1.2 / 1.8 / 2.4 mg) vs. placebo over 40 weeks, plus lifestyle intervention.
Findings:Dose-dependent weight reduction versus placebo; high completion (93%). GI effects most common.